ScholarLens Back to search
2009•PubMedRequires access

Maximizing the clinical benefit of novel therapies in multiple myeloma.

Jacob P. Laubach, Constantine S. Mitsiades, Kenneth C. Anderson, Paul G. Richardson

Open publisher page 1 citations

Abstract

In this issue of ONCOLOGY, Dingli and Rajkumar provide an expert review of novel therapies in multiple myeloma. As their work underscores, the rapid clinical development of the immunomodulatory drugs—specifically thalidomide (Thalomid) and lenalidomide (Revlimid), and the proteasome inhibitor bor­tezomib (Velcade)—has changed the therapeutic landscape of this disease, resulting in significant improvements in patient outcomes.[1]

About this research paper

What this paper is about

In this issue of ONCOLOGY, Dingli and Rajkumar provide an expert review of novel therapies in multiple myeloma. As their work underscores, the rapid clinical development of the immunomodulatory drugs—specifically thalidomide (Thalomid) and lenalidomide (Revlimid), and the proteasome inhibitor bor­tezomib (Velcade)—has changed the therapeutic landscape of this disease, resulting in significant improvements in patient outcomes.[1]

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

In this issue of ONCOLOGY, Dingli and Rajkumar provide an expert review of novel therapies in multiple myeloma. As their work underscores, the rapid clinical development of the immunomodulatory drugs—specifically thalidomide (Thalomid) and lenalidomide (Revlimid), and the proteasome inhibitor bor­tezomib (Velcade)—has changed the therapeutic landscape of this disease, resulting in significant improvements in patient outcomes.[1]

Key concepts: Lenalidomide, Thalidomide, Multiple myeloma, Medicine, Bortezomib, Proteasome inhibitor, Oncology, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Maximizing the clinical benefit of novel therapies in multiple myeloma. — Research Paper | ScholarLens